Medivation Inc and Astellas Pharma Inc
Medivation and Astellas Announce Final Results from the Phase 3 Prevail Trial of Enzalutamide in Men with Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy
San Francisco And Tokyo (ots/PRNewswire) - --Study demonstrates statistically significant benefits in overall survival, radiographic progression-free survival, and a delay (17 months) in the time to initiation of chemotherapy-- Medivation Inc. and Astellas Pharma Inc. announced final results on the primary and ...
mehr